Prophylactic brain irradiation was associated with a significant improvement in disease-free survival and a significant reduction in likelihood of developing brain metastases.
The Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab; Genentech), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Whole-genome sequencing of tumor specimens from patients with chemoresistant SCLC showed evidence of the deletion of multiple tumor suppressor genes.
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
NSCLC characterized by ALK or EGFR molecular alterations produced different findings on CT scan images.
The Guardant360 assay is as effective as traditional tumor-based genotyping assays in identifying genomic alterations, according to researchers.
This study was presented at the 2019 International Congress on Targeted Anticancer Therapies (TAT) in Paris, France, from February 25-27, 2019. Dr Jun Sato of the National Cancer Center Hospital, Japan is the lead author of this study.1 Results from a retrospective study evaluating the focus of early-phase clinical trials of investigational drug candidates in…
Currently used assays that gauge potential response to immune checkpoint inhibitors have limited predictive value, noted researchers.
Assessments of MET copy number gain are not predictive of benefit from TKI therapy in EGFR-mutant NSCLC, according to researchers.
The Lung-MAP trial, which will allow multiple tumor biomarker-specific treatments to be evaluated in a single umbrella study, is now open to all patients with NSCLC.
Individuals with early-stage EGFR-mutant NSCLC who were administered erlotinib showed improved 2-year DFS compared with genotype-matched historical controls.
Pyrotinib showed activity in HER2-positive non-small cell lung cancer, both in preclinical experiments and in patients enrolled in a phase 2 trial.
Use of durvalumab consolidation therapy in all eligible patients with NSCLC was deemed cost-effective, despite its incremental budgetary consequence of $768 million in year 1.
The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
Researchers found that recurrences were rare for patients receiving adjuvant erlotinib.
Researchers reported that ablation of pulmonary malignant tumors may be a safe treatment option in select patients.
Combination therapy showed activity in epidermal growth factor receptor-mutated, mesenchymal-epithelial transition factor-dysregulated non-small-cell lung cancer.
This trial in NSCLC was terminated early when the investigational drug become unavailable following the dissolution of a partnership between the drug’s codevelopers.
Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.
Scientific models project a continued decrease in lung cancer mortality.